{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:34:52Z","timestamp":1787164492826,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Febrile neutropenia promotes renal drug excretion. Adult and pediatric patients with febrile neutropenia exhibit a lower vancomycin concentration\/dose (relative to bodyweight) ratio than those with other infections. In pediatric patients, renal function relative to bodyweight varies depending on age, and vancomycin clearance is age dependent. This study aimed to analyze the effects of febrile neutropenia on the pharmacokinetics of vancomycin in age-stratified pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective, single-center, observational cohort study analyzed 112 hospitalized pediatric patients who met the selection criteria and intravenously received vancomycin at the Department of Pediatrics of the Oita University Hospital between April 2011 and October 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The febrile neutropenia (n = 46) cohort exhibited a significantly higher estimated glomerular filtration rate than the nonfebrile neutropenia (n = 66) cohort. Compared with those in the nonfebrile neutropenia cohort, the daily vancomycin dose relative to bodyweight and vancomycin clearance were significantly higher, and the vancomycin trough concentration and vancomycin concentration\/dose ratio were significantly lower in the febrile neutropenia cohort. In the age groups of 1\u20136 and 7\u201312 years, compared with those in the nonfebrile neutropenia cohort, the vancomycin concentration\/dose ratio was significantly lower, and vancomycin clearance was significantly higher in the febrile neutropenia cohort. Univariate and multivariate analyses identified febrile neutropenia as the independent factor influencing vancomycin concentration\/dose ratio and clearance only in pediatric patients aged 1\u20136 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Increased initial dosage and therapeutic drug monitoring-guided dose optimization are critical for the therapeutic efficacy of vancomycin in pediatric patients with febrile neutropenia, especially in those aged 1\u20136 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000978","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:30Z","timestamp":1657670430000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Association of Vancomycin Trough Concentration and Clearance With Febrile Neutropenia in Pediatric Patients"],"prefix":"10.1097","volume":"44","author":[{"given":"Erino","family":"Amano","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7971","authenticated-orcid":false,"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Oita University, Faculty of Medicine, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Oita University, Faculty of Medicine, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","article-title":"Febrile neutropenia in hematologic malignancies","volume":"8","author":"Keng","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R3-20250603","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","article-title":"The dosing and monitoring of vancomycin: what is the best way forward?","volume":"53","author":"Drennan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/jac\/dkab048","article-title":"AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics","volume":"76","author":"Jorgensen","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jiac.2021.01.015","article-title":"The optimal trough-guided monitoring of vancomycin in children: systematic review and meta-analyses","volume":"27","author":"Moriyama","year":"2021","journal-title":"J Infect Chemother"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"106408","DOI":"10.1016\/j.ijantimicag.2021.106408","article-title":"Population pharmacokinetics of continuous infusion of piperacillin\/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000346","article-title":"Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FTD.0000000000000318","article-title":"Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization","volume":"38","author":"Guilhaumou","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkab302","article-title":"Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations","volume":"76","author":"Shimamoto","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/IDR.S239095","article-title":"A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia","volume":"13","author":"He","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00007691-199812000-00005","article-title":"Population pharmacokinetics of vancomycin in Japanese pediatric patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1248\/bpb1978.8.246","article-title":"A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers","volume":"8","author":"Yamaoka","year":"1985","journal-title":"J Pharmacobiodyn"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40272-015-0122-8","article-title":"Pediatric assessment of vancomycin empiric dosing (PAVED): a retrospective review","volume":"17","author":"Rainkie","year":"2015","journal-title":"Paediatr Drugs"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy","volume":"28","author":"Claus","year":"2013","journal-title":"J Crit Care"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/cc10262","article-title":"A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance","volume":"15","author":"Baptista","year":"2011","journal-title":"Crit Care"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrneph.2011.92","article-title":"Implications of augmented renal clearance in critically ill patients","volume":"7","author":"Udy","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/phar.2617","article-title":"Scoping review of augmented renal clearance in critically ill pediatric patients","volume":"41","author":"Rhoney","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/antibiotics10050504","article-title":"Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy","volume":"10","author":"\u00c1lvarez","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1345\/aph.1R097","article-title":"Pharmacokinetics and Monte Carlo simulations of doripenem in patients with febrile neutropenia","volume":"46","author":"Stein","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/AAC.02340-14","article-title":"Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy","volume":"58","author":"Sime","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/FTD.0000000000000341.","article-title":"Gentamicin pharmacokinetics and monitoring in pediatric patients with febrile neutropenia","volume":"38","author":"Bialkowski","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/jac\/dkz270","article-title":"Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen","volume":"74","author":"Thorsted","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient: concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections","volume":"32","author":"Frymoyer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/PCC.0000000000001228","article-title":"Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients","volume":"18","author":"Avedissian","year":"2017","journal-title":"Pediatr Crit Care Med"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:00:29Z","timestamp":1748970029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000978","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"2021-10-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}